Solid Earnings for JNJ Offset Covid-19 Vaccine Trial Setback

Author:
Publish date:
Video Duration:
3:09

A solid third-quarter earnings beat was overshadowed on Tuesday by a pause in Johnson &Johnson's  (JNJ) - Get Report Janssen unit's Covid-19 vaccine trial.

Johnson & Johnson (JNJ) - Get Report on Tuesday reported better-than-expected third-quarter earnings as demand for its drugs as well consumer products and equipment all increased.

J&J said it earned $5.87 billion, or $2.20 an adjusted share, vs. $5.67 billion, or $2.12 a share a year ago. Analysts polled by FactSet had been expecting earnings of $1.98 a share. Revenue came in at $21.08 billion, above last year’s $20.73 billion and also above analysts’ estimates of $20.21 billion.  

 The results came as J&J announced a pause in its Covid-19 vaccine study due to an unexplained illness in a study participant, which in turn caused its shares to slump in premarket trading on Tuesday.

A document sent to outside researchers running the 60,000-patient clinical trial said that a “pausing rule” has been met, that the online system used to enroll patients in the study has been closed, and that the data and safety monitoring board — an independent committee that watches over the safety of patients in the clinical trial — would be convened.

Separately, Johnson & Johnson raised its full-year guidance, saying it now expects expects per-share earnings of between $7.95 and $8.05, up from its previous forecast in July of between $7.75 and $7.95.

Watch More on the Coronavirus Pandemic From TheStreet.com: